Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe - Seite 3

The 38 GEICAM clinical sites will be listed on clinicaltrials.gov with an interactive map and are shown below.

Albacete

Albacete University Hospital Complex

Alicante

Dr. Balmis General University Hospital

Badajoz

University Hospital of Badajoz

Barcelona

Clinic Hospital of Barcelona
Hospital del Mar

Caceres

San Pedro de Alcántara Hospital

Cordoba

Reina Sofia University Hospital

Fuenlabrada (Madrid)

University Hospital of Fuenlabrada

Galdácano

Galdakao-Usansolo Hospital

Granada

San Cecilio Clinical University Hospital

Jaén

University Hospital of Jaén

Jerez de La Frontera

University Hospital of Jerez de la Frontera

La Laguna (Tenerife)

University Hospital of the Canary Islands

Lerida

Arnau de Vilanova University Hospital of Lleida

Madrid

Gregorio Marañón General University Hospital
12 de Octubre University Hospital
Fundación Jiménez Díaz University Hospital
HM Sanchinarro University Hospital
Infanta Leonor University Hospital

Majadahonda (Madrid)

Puerta de Hierro Majadahonda University Hospital

Malaga

Regional University Hospital of Malaga

Manresa (Barcelona)

Althaia, Manresa University Care Network

Murcia

Morales Meseguer University General Hospital

Virgen de la Arrixaca University Clinic Hospital

Palma, Majorca (Balearic Islands)

Son Espases University Hospital

San Juan (Alicante)

San Juan University Hospital of Alicante

San Sebastian

Donostia University Hospital

Sant Cugat del Valles (Barcelona)

General University Hospital of Catalonia - Quirónsalud Group

Santa Cruz De Tenerife

Nuestra Señora de Candelaria University Hospital

Santiago de Compostela

University Clinical Hospital of Santiago

Seville

Virgen del Rocío University Hospital
Virgen Macarena University Hospital

Toledo

University Hospital of Toledo

Valencia

General University Hospital Consortium of Valencia
Valencian Institute of Oncology Foundation
University Clinical Hospital of Valencia
Arnau de Vilanova University Hospital of Valencia

Zaragoza

Miguel Servet University Hospital

About FLAMINGO-01 and GLSI-100

FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US clinical sites from university-based hospitals and cooperative networks with plans to expand into Europe and to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients will be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types will be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater.